CN108144060A - 一类通过调控yb-1磷酸化治疗单核细胞趋化蛋白-1参与的疾病的药物及其筛选方法 - Google Patents

一类通过调控yb-1磷酸化治疗单核细胞趋化蛋白-1参与的疾病的药物及其筛选方法 Download PDF

Info

Publication number
CN108144060A
CN108144060A CN201810175137.9A CN201810175137A CN108144060A CN 108144060 A CN108144060 A CN 108144060A CN 201810175137 A CN201810175137 A CN 201810175137A CN 108144060 A CN108144060 A CN 108144060A
Authority
CN
China
Prior art keywords
substance
drug
phosphorylations
mcp
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201810175137.9A
Other languages
English (en)
Chinese (zh)
Inventor
刘斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilin Zhongtai Biological Technology Co Ltd
Original Assignee
Jilin Zhongtai Biological Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jilin Zhongtai Biological Technology Co Ltd filed Critical Jilin Zhongtai Biological Technology Co Ltd
Priority to PCT/CN2018/080675 priority Critical patent/WO2019024518A1/fr
Publication of CN108144060A publication Critical patent/CN108144060A/zh
Priority to PCT/CN2018/098075 priority patent/WO2019024875A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
CN201810175137.9A 2017-08-03 2018-03-02 一类通过调控yb-1磷酸化治疗单核细胞趋化蛋白-1参与的疾病的药物及其筛选方法 Withdrawn CN108144060A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2018/080675 WO2019024518A1 (fr) 2017-08-03 2018-03-27 Médicament pour le traitement d'une maladie impliquant la protéine chimioattractive des monocytes de type 1 (mcp-1) par ajustement de la phosphorylation de yb-1
PCT/CN2018/098075 WO2019024875A1 (fr) 2017-08-03 2018-08-01 Utilisation d'une substance régulant directement ou indirectement la phosphorylation d'yb-1 dans la préparation d'un médicament pour le traitement d'une maladie provoquée par des facteurs inflammatoires

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710657706 2017-08-03
CN2017106577069 2017-08-03

Publications (1)

Publication Number Publication Date
CN108144060A true CN108144060A (zh) 2018-06-12

Family

ID=62456348

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810175137.9A Withdrawn CN108144060A (zh) 2017-08-03 2018-03-02 一类通过调控yb-1磷酸化治疗单核细胞趋化蛋白-1参与的疾病的药物及其筛选方法
CN201810783225.7A Active CN109200287B (zh) 2017-08-03 2018-07-17 直接或间接调控yb-1磷酸化的物质在制备治疗炎性因子所致疾病的药物方面的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810783225.7A Active CN109200287B (zh) 2017-08-03 2018-07-17 直接或间接调控yb-1磷酸化的物质在制备治疗炎性因子所致疾病的药物方面的应用

Country Status (2)

Country Link
CN (2) CN108144060A (fr)
WO (1) WO2019024518A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019024875A1 (fr) * 2017-08-03 2019-02-07 吉林众泰生物技术有限公司 Utilisation d'une substance régulant directement ou indirectement la phosphorylation d'yb-1 dans la préparation d'un médicament pour le traitement d'une maladie provoquée par des facteurs inflammatoires
WO2024108386A1 (fr) * 2022-11-22 2024-05-30 中国科学院深圳先进技术研究院 Utilisation d'un anticorps neutralisant anti-mcp1 dans la préparation d'un médicament pour le traitement d'une inflammation systémique provoquée par des maladies neurodégénératives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109908A1 (fr) * 2006-03-29 2007-10-04 The University Of British Columbia Leures thérapeutiques de la phosphorylation par le yb-1
KR101903838B1 (ko) * 2015-09-07 2018-10-02 동국대학교 산학협력단 유방암 관련 stk32c 유전자 및 이의 용도

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019024875A1 (fr) * 2017-08-03 2019-02-07 吉林众泰生物技术有限公司 Utilisation d'une substance régulant directement ou indirectement la phosphorylation d'yb-1 dans la préparation d'un médicament pour le traitement d'une maladie provoquée par des facteurs inflammatoires
WO2024108386A1 (fr) * 2022-11-22 2024-05-30 中国科学院深圳先进技术研究院 Utilisation d'un anticorps neutralisant anti-mcp1 dans la préparation d'un médicament pour le traitement d'une inflammation systémique provoquée par des maladies neurodégénératives

Also Published As

Publication number Publication date
WO2019024518A1 (fr) 2019-02-07
CN109200287A (zh) 2019-01-15
CN109200287B (zh) 2021-02-09

Similar Documents

Publication Publication Date Title
US6777388B1 (en) Leptin-related peptides
RU2365382C2 (ru) Композиции и способы для регуляции развития сосудов
US20060234271A1 (en) Methods for the diagnosis and treatment of metastatic prostate tumors
JP2005537253A (ja) 組織損傷の治療におけるおよび／または組織修復を促進するためのｈｍｇｂ１の使用
KR20100099249A (ko) 세포막 재봉합을 조절하기 위한 조성물 및 방법
JP6565121B2 (ja) 代謝障害を治療する方法
US20100111964A1 (en) Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders
KR100553300B1 (ko) 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
CN103228295B (zh) 一种限制急性心肌缺血后微血管损伤的方法
JP2002515444A (ja) 骨粗鬆症の治療方法
Kong et al. Anti–neuropilin‐1 peptide inhibition of synoviocyte survival, angiogenesis, and experimental arthritis
CN108144060A (zh) 一类通过调控yb-1磷酸化治疗单核细胞趋化蛋白-1参与的疾病的药物及其筛选方法
Schaffner-Reckinger et al. The actin-bundling protein L-plastin—A double-edged sword: Beneficial for the immune response, maleficent in cancer
KR20160048103A (ko) Vegf-c 및 ccbe1의 치료적 용도
ES2320139T3 (es) Uso de t-cadherina soluble para el tratamiento de trastornos metabolicos.
ES2402096T3 (es) Uso de proteínas relacionadas con saposina para prevenir y tratar la obesidad, diabetes y/o síndrome metabólico
TW200831898A (en) Treatment of insulin resistance
WO2001096372A2 (fr) Transporteurs de zinc
JP2004508827A (ja) カルシウム結合タンパク質
JP2003523723A (ja) ヘルマンスキー−パドラック症候群タンパク質相互作用タンパク質およびその使用の方法
JP2004008027A (ja) ｃＡＭＰの産生活性を有する新規ペプチド
US7622443B2 (en) Method for inhibiting pro-angiogenic activities of endothelial cells selectively at a site of neoangiogenesis in a mammal by administration of the extracellular domain of D1-1 polypeptides
WO2018042182A1 (fr) Compositions et leurs utilisations
EP2358871B1 (fr) Anticorps spécifique de site de phosphorylation d erk1/2
CA2369156A1 (fr) Animal transgenique non humain dont les cellules germinales et les cellules somatiques contiennent une mutation knockout dans l'adn codant pour 4e-bp1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20180612